ATAI Life Sciences Stock Discussion

$ATAI Life Sciences (ATAI.US)$
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
atai Life Sciences (NASDAQ: ATAI)announced positive preliminary results from its Phase 1b trial of VLS-01, a proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT). The trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared to intravenous DMT in healthy participants.
Key findings include:
D...

$ATAI Life Sciences (ATAI.US)$ Weird things happen when I show up . I'll take a position.  One of my dogs of war says so.

$ATAI Life Sciences (ATAI.US)$ Thank you for your work it's showing.

$Kazia Therapeutics (KZIA.US)$
You should check out $ATAI Life Sciences (ATAI.US)$ as well.  😉

$Biodexa Pharmaceuticals (BDRX.US)$
$ATAI Life Sciences (ATAI.US)$  looks good too!  It'll be interesting to see the advancements coming with their medicine.  Especially with John Hopkins University doing similar research.

$Silo Pharma (SILO.US)$
$ATAI Life Sciences (ATAI.US)$  looks good too!  It'll be interesting to see the advancements coming with their medicine.  Especially with John Hopkins University doing similar research.

$Catheter Precision (VTAK.US)$
$ATAI Life Sciences (ATAI.US)$  looks pretty good too!

$ATAI Life Sciences (ATAI.US)$ atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
• ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hour...

$ATAI Life Sciences (ATAI.US)$
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
atai Life Sciences has provided an update on Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a synthetic psilocin formulation designed for a consistent and shorter treatment duration of approximately two hours. The Phas...